Location History:
- Monroe, LA (US) (2014)
- Riyadh, SA (2015)
Company Filing History:
Years Active: 2014-2015
Title: **Fathy A. Behery: A Pioneer in Anticancer Research**
Introduction
Fathy A. Behery, a notable inventor based in Riyadh, Saudi Arabia, has made significant contributions to the field of pharmaceuticals through his innovative work in anticancer agents. With a total of two granted patents, his research focuses on the development of tocotrienol derivatives, which have potential applications in cancer treatment.
Latest Patents
Fathy's most recent patents involve detailed compositions of matter, specifically the compounds (R)-2,5,6,8-tetramethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine and (R)-2,6,8-trimethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine. These patents not only describe the compounds but also outline the methods of preparation and their application as anticancer agents, showcasing Fathy’s dedication to advancing medical science.
Career Highlights
Currently, Fathy A. Behery is associated with First Tech International Limited, where he applies his expertise in innovative pharmaceuticals. His work has helped shape the understanding and potential uses of tocotrienol derivatives in the medical field, demonstrating his commitment to research and development.
Collaborations
Throughout his career, Fathy has collaborated with distinguished professionals, notably Khalid A. El Sayed and Paul W. Sylvester. These collaborations have fostered a dynamic environment for research and have contributed to the successful development of cutting-edge pharmaceutical solutions.
Conclusion
Fathy A. Behery stands out as a dedicated inventor in the realm of anticancer research. His innovative work in tocotrienol derivatives highlights his commitment to improving healthcare outcomes. As he continues his work with First Tech International Limited, the potential for further advancements in cancer treatment remains promising, solidifying his legacy as a key contributor to medical innovation.